°£Áú - ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, ¼¼°è ¹× Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® º¸°í¼­ : À¯Çüº°, Åõ¿© °æ·Îº°, Ä¡·á À¯Çüº°, ¿¬·É´ëº°, À¯Åë ä³Îº°, Áö¿ªº°
Epilepsy Market Size and Forecasts, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Treatment Type, Age Group, Distribution Channel, and Geography
»óǰÄÚµå : 1450838
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 230 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,450 £Ü 6,368,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 6,450 £Ü 9,231,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,450 £Ü 12,093,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

°£Áú ½ÃÀå ±Ô¸ð´Â 2022³â 77¾ï ´Þ·¯¿¡¼­ 2030³â 107¾ï ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022-2030³â CAGRÀº 4.1%·Î ¿¹ÃøµË´Ï´Ù.

°£ÁúÀº Àü ¼¼°èÀûÀ¸·Î °¡Àå ÈçÇÑ ¸¸¼º ½Å°æÁúȯ Áß ÇϳªÀÔ´Ï´Ù. ³úÀÇ ºñÁ¤»óÀûÀÎ Àü±âÀû Ȱµ¿À» ¼ö¹ÝÇÏ´Â ÀÌ ÁúȯÀº °¡Àӱ⠹̱¹ ¿©¼º 100¸¸ ¸í ÀÌ»óÀÌ ¾Î°í ÀÖ½À´Ï´Ù. °£Áú À¯º´·ü Áõ°¡¿Í °£Áú Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â °£Áú ½ÃÀå ±Ô¸ð È®´ë¿¡ ±â¿©ÇÏ´Â ÁÖ¸ñÇÒ ¸¸ÇÑ ¿äÀÎÀÔ´Ï´Ù. Ç×°£Áú¾à(AED)ÀÇ Åõ¿©´Â ÀϹÝÀûÀ¸·Î °£Áú¿¡ ´ëÇÑ 1Â÷ Ä¡·á·Î ºÒ¸³´Ï´Ù. °£Áú ȯÀÚÀÇ ¾à 80%´Â °³¹ßµµ»ó±¹¿¡ °ÅÁÖÇϰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ»Ó¸¸ ¾Æ´Ï¶ó ¼ºÀο¡¼­µµ °£Áú Ä¡·áÀÇ ´ëºÎºÐÀº ¾à¹° ¿ä¹ý(´Üµ¶ ¶Ç´Â º´¿ë ¿ä¹ý)À» ±â¹ÝÀ¸·ÎÇÏ¸ç ¼ö¼ú, ½Å°æ Á¶Àý ¿ä¹ý, ÄÉÅäÁ¦´Ð ´ÙÀÌ¾îÆ®¿Í °°Àº ³ª¸ÓÁö Ä¡·á Á¢±Ù¹ýÀº ´ú ÀÚÁÖ »ç¿ëµË´Ï´Ù. ±×·¯³ª Á¦Ç° ȸ¼ö°¡ °£Áú ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

¿¬·É´ëº° ÀλçÀÌÆ®

¿¬·É´ëº°·Î °£Áú ½ÃÀåÀº ¼ºÀΰú ¼Ò¾Æ·Î ±¸ºÐµÇ¸ç, 2022³â °£Áú ½ÃÀå Á¡À¯À²Àº ¼ºÀÎÀÌ ´õ Ŭ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ 2022-2030³â ½ÃÀå¿¡¼­ ´õ ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °£ÁúÀº ¼ºÀο¡°Ô ¹ßº´Çϱ⠽±´Ù. ³ú ±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áúȯ(¾ËÃ÷ÇÏÀ̸Ӻ´ µî), ³úÁ¾¾ç, ³úÁ¹Áß, µÎºÎ ¿Ü»ó µî ¼ºÀÎÀÇ ³úÀüÁõ À§Çè ¿äÀÎÀÌ ¸¹½À´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â 18¼¼ ÀÌ»ó ¼ºÀÎ 300¸¸ ¸íÀÌ È°µ¿¼º °£ÁúÀ» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ Áß °ÅÀÇ 100¸¸ ¸íÀÌ 55¼¼ ÀÌ»óÀÔ´Ï´Ù. Àα¸ °í·ÉÈ­¿¡ µû¶ó ¾ÕÀ¸·Î ´õ ¸¹Àº ³ëÀÎÀÌ °£ÁúÀ» ¾Î°Ô µÉ °¡´É¼ºÀÌ ÀÖÀ¸¸ç, 2021³â¿¡´Â ¹Ì±¹ ¼ºÀÎÀÇ 1.1%(-286¸¸ ¸í)°¡ Ȱµ¿¼º °£ÁúÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ¾à¹° ¿ä¹ý°ú Ä¡·á Àü·«Àº ¼ºÀΠȯÀÚ¸¦ ¿ì¼±½ÃÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, ÀÌ´Â ÀÌ ¿¬·É´ëÀÇ °£Áú Àα¸ Åë°èÇÐÀû À¯º´·ü°ú ÀÏÄ¡ÇÕ´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚ ±â¹Ý ÀλçÀÌÆ®

°£Áú ½ÃÀåÀº À¯Åë ä³Î¿¡ µû¶ó º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ±âŸ·Î ºÐ·ùµÇ¸ç, º´¿ø ¾à±¹ ºÎ¹®Àº 2022³â °£Áú ½ÃÀå Á¡À¯À²ÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¼Ò¸Å ¾à±¹ ºÎ¹®Àº 2022-2030³â µ¿¾È ½ÃÀå¿¡¼­ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼Ò¸Å ¾à±¹ ¸ÅÀåÀº 󹿾à, ÀÏ¹Ý ÀǾàǰ, ÀϺΠºü¸£°Ô ¿òÁ÷ÀÌ´Â ¼ÒºñÀ縦 ÆÇ¸ÅÇÏ°í °ü·Ã ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ÃֽŠ¼Ò¸Å ¾à±¹ üÀÎÀº µðÁöÅÐÈ­, Á¶Á÷È­, ÷´ÜÈ­µÇ¾î ÀǾàǰ Àç°í¸¦ ÃßÀûÇϰí 100% ½Å·ÚÇÒ ¼öÀÖ´Â Á¦Ç°À» ÆÇ¸Å ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼Ò¸Å ¾à±¹ üÀÎÀº ÀÇ·áºñ û±¸ ¹× º¸Çè ½ÅûÀ» ÇÏ´Â ¼ÒºñÀÚ¿¡°Ô °íºÎ°¡°¡Ä¡ ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ °ú°Å û±¸¼­ ¹× ¸Þ¸ðÀÇ ¼öÁ¤À» ¿äûÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ°¡ ó¹æÀüÀ» ÀÛ¼ºÇÏ°í ¾à»ç¿¡°Ô »ó´ãÀ» ¹ÞÀ» ¼ö ÀÖ´Â Æí¸®ÇÑ À§Ä¡¿¡ ÀÖ½À´Ï´Ù.

¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(Centers for Disease Control and Prevention), ¼¼°èº¸°Ç±â±¸(WHO), ij³ª´Ù ½Å°æ °Ç°­ ÀÚ¼±´Üü(Neurological Health Charities Canada) µîÀº °£Áú ½ÃÀå º¸°í¼­ ÀÛ¼º ½Ã Âü°íÇÑ 1Â÷ ¹× 2Â÷ Á¤º¸ Áß ÇϳªÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå °£Áú ½ÃÀå ±¸µµ

Á¦5Àå °£Áú ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå °£Áú ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

Á¦7Àå °£Áú ½ÃÀå ºÐ¼® : À¯Çüº°

Á¦8Àå °£Áú ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

Á¦9Àå °£Áú ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°

Á¦10Àå °£Áú ½ÃÀå ºÐ¼® : ¿¬·ÉÃþº°

Á¦11Àå °£Áú ½ÃÀå ºÐ¼® : À¯Åë ä³Îº°

Á¦12Àå °£Áú ½ÃÀå : Áö¿ªº° ºÐ¼®

Á¦13Àå ¾÷°è »óȲ

Á¦14Àå ±â¾÷ °³¿ä

Á¦15Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The epilepsy market size is expected to grow from US$ 7.7 billion in 2022 to US$ 10.7 billion by 2030; it is projected to register a CAGR of 4.1% during 2022-2030.

Epilepsy is one of the most common chronic neurological disorders across the world. Associated with an abnormal electrical activity in the brain, this disorder affects over 1 million American women of childbearing age. The rising prevalence of epilepsy and increasing investments in the development of epilepsy therapies are noteworthy factors contributing to the expansion of the epilepsy market size. The administration of anti-epileptic drugs (AEDs) is usually referred to as the first-line treatment for epilepsy. Approximately 80% of the people suffering from epilepsy are from developing countries. In children as well as adults, the treatment of epilepsy is mostly based on the use of drugs (either in monotherapy or combined therapy), while the remaining treatment approaches, such as surgery, neuromodulation, and ketogenic diet, are used at a lesser frequency. However, the recall of products hinders the epilepsy market growth.

Age Group-Based Insights

Based on age group, the epilepsy market is segmented into adults and children. The adults segment held a larger epilepsy market share in 2022. It is further expected to register a higher CAGR in the market during 2022-2030. Epilepsy is more likely to develop in adults as some risk factors for this disease are more common in adults; these include diseases affecting brain function (such as Alzheimer's disease), brain tumors, strokes, and head injuries. According to the Centers for Disease Control and Prevention (CDC), 3 million adults aged 18 or older are living with active epilepsy in the US. Nearly 1 million of these adults are aged 55 or older. As the population ages, even more older people are likely to suffer from epilepsy in the coming years. In 2021, 1.1% of US adults (~2.86 million adults) reported active epilepsy. Thus, medications and treatment strategies often prioritize adult patients, aligning with the demographic prevalence of epilepsy in this age group.

End User-Based Insights

Based on distribution channel, the epilepsy market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest epilepsy market share in 2022. In addition, the retail pharmacies segment is expected to register the highest CAGR in the market during 2022-2030. Retail pharmacy stores sell prescription drugs, over-the-counter drugs, and some fast-moving consumer goods, along with providing related services. Modern retail pharmacy chains are digitized, organized, and tech-enabled, which allows them to track medication inventories and sell 100% reliable goods. In addition, retail pharmacy chains provide value-added services for consumers opting for medical claims or insurance filings. They can also be requested to refurbish previous bills or memos. Moreover, their locations make them accessible for patients to fill their prescriptions and receive counseling from pharmacists.

Centers for Disease Control and Prevention, the World Health Organization, and Neurological Health Charities Canada are among the primary and secondary sources referred to while preparing the epilepsy market report.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Epilepsy Market Landscape

5. Epilepsy Market - Key Market Dynamics

6. Epilepsy Market - Global Market Analysis

7. Epilepsy Market Analysis - by Type

8. Epilepsy Market Analysis - by Route of Administration

9. Epilepsy Market Analysis - by Treatment Type

10. Epilepsy Market Analysis - by Age Group

11. Epilepsy Market Analysis - by Distribution Channel

12. Epilepsy Market - Geographical Analysis

13. Industry Landscape

14. Company Profiles

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â